Skip to main content
TipRanks
Go Ultimate75% OFF

BioMarin Pharmaceutical (BM8) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

BM8 Analyst Ratings

Moderate Buy
23Ratings
17Buy6Hold0Sell
Based on 23 analysts giving stock ratings to BioMarin Pharmaceutical in the past 3 months

BM8 Stock 12 Month Forecast

€80.50▲(58.21% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is EUR 80.50 with a high forecast of EUR 108.87 and a low forecast of EUR 54.44. The average price target represents a 58.21% change from the last price of EUR 50.88.
Highest Price Target€108.87Average Price Target€80.50Lowest Price Target€54.44

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:BM8
Price TargetArticle
H.C. Wainwright€54.44hold6.99%UpsideReiterated11/16/26
Morgan Stanley€107.96→€93.45buy83.66%UpsideAssigned11/13/26
Evercore ISI€108.87buy113.97%UpsideReiterated11/13/26
Barclays€103.43buy103.28%UpsideReiterated11/04/26
J.P. Morgan€78.93→€78.02buy53.35%UpsideReiterated11/04/26
Wells Fargo€72.58buy42.65%UpsideAssigned11/03/26
Stifel Nicolaus€63.51→€59.88hold17.69%UpsideReiterated11/03/26
Wedbush€85.28→€80.75buy58.70%UpsideAssigned11/03/26
UBS€79.84buy56.91%UpsideReiterated11/03/26
Oppenheimer€88.00→€85.28buy67.61%UpsideReiterated11/03/26
TD Cowen€108.87buy113.97%UpsideReiterated11/03/26
Citi€68.95buy35.52%UpsideReiterated11/02/26
RBC Capital€56.25→€54.44hold6.99%UpsideReiterated11/02/26
Cantor Fitzgerald€78.02buy53.35%UpsideReiterated11/02/26
Bank of America Securities€78.02→€75.30buy48.00%UpsideReiterated11/02/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PLSEPulse Biosciences
SLDBSolid Biosciences
RZLTRezolute
IMUXImmunic
MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

3 Months
Christopher Raymond
Christopher RaymondRaymond James
Success Rate15/36 ratings generated profit
42%
Average Return
-0.44%

Copying Christopher Raymond's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of -0.44% per trade.

1 Year
Cory Kasimov
Cory KasimovEvercore ISI
Success Rate19/43 ratings generated profit
44%
Average Return
-4.32%

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 44.19% of your transactions generating a profit, with an average return of -4.32% per trade.

2 Years
Phil Nadeau
Phil NadeauTD Cowen
Success Rate12/28 ratings generated profit
43%
Average Return
-5.24%

Copying Phil Nadeau's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -5.24% per trade.

BM8 Analyst Recommendation Trends

020406080Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for BM8
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy2516172623
Buy710171712
Hold131415138
Sell00000
Strong Sell00000
total4540495643

In the current month, BM8 has received 35 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BM8 average Analyst price target in the past 3 months is 80.50.

BM8 Financial Forecast

€-2€-1€0€1€2Q1 2026Q3 2026Q4 2026
High€0.87
Consensus€0.74
Low€0.60

BM8 Earnings Forecast

Next quarter’s earnings estimate for BM8 is EUR 0.74 with a range of EUR 0.60 to EUR 0.87. The previous quarter’s EPS was EUR 0.21. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€703.8M€781.2M€858.5M€935.9M€1BQ1 2026Q3 2026Q4 2026
High€1.01B
Consensus€985M
Low€956M

BM8 Sales Forecast

Next quarter’s sales forecast for BM8 is EUR 984.59M with a range of EUR 956.30M to EUR 1.01B. The previous quarter’s sales results were EUR 926.12M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

BM8 Stock Forecast FAQ

What is DE:BM8’s average 12-month price target, according to analysts?
Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is €80.50.
What is DE:BM8’s upside potential, based on the analysts’ average price target?
BioMarin Pharmaceutical has 58.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BioMarin Pharmaceutical a Buy, Sell or Hold?
BioMarin Pharmaceutical has a consensus rating of Moderate Buy, which is based on 17 buy ratings, 6 hold ratings and 0 sell ratings.
What is BioMarin Pharmaceutical’s share price target?
The average share price target for BioMarin Pharmaceutical is €80.50. This is based on 23 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €108.87, and the lowest forecast is €54.44. The average share price target represents a 58.21% increase from the current price of €50.88.
What do analysts say about BioMarin Pharmaceutical?
BioMarin Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Street analysts.
How can I buy shares of BioMarin Pharmaceutical?
To buy shares of DE:BM8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.